Sarilumab

This recommendation applies to acute COVID-19 in adults. Some of our recommendations vary according to the severity of COVID-19 illness. Definitions of the categories are based on the World Health Organization (WHO) criteria and can be viewed by clicking the plus (+) signs below.

RECOMMENDATION: Sarilumab, an IL 6 inhibitor, has been evaluated as an alternative to Tocilizumab in the treatment of COVID-19 illness. The group recommended that Sarilumab should not be used for Covid-19 illness (moderate certainty evidence, strong recommendation). There was no evidence of benefit compared with placebo in three well conducted randomized controlled trials.

DATE OF RECOMMENDATION: